Wealth Enhancement Advisory Services LLC Boosts Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Wealth Enhancement Advisory Services LLC increased its holdings in Becton, Dickinson and Company by 9.9% during the second quarter, owning 90,225 shares valued at approximately $15.89 million.
• Becton, Dickinson and Company reported quarterly earnings per share of $3.68, exceeding analysts' estimates, and had a revenue of $5.51 billion, marking a 10.4% increase from the previous year.
• The company declared a quarterly dividend of $1.04 per share, yielding 2.2%, with a payout ratio of approximately 74.82%.

Wealth Enhancement Advisory Services LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 90,225 shares of the medical instruments supplier's stock after buying an additional 8,115 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Becton, Dickinson and Company were worth $15,894,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mn Services Vermogensbeheer B.V. increased its holdings in shares of Becton, Dickinson and Company by 1.5% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 107,304 shares of the medical instruments supplier's stock valued at $18,483,000 after purchasing an additional 1,600 shares during the period. Tompkins Financial Corp increased its holdings in shares of Becton, Dickinson and Company by 123.1% in the second quarter. Tompkins Financial Corp now owns 1,450 shares of the medical instruments supplier's stock valued at $250,000 after purchasing an additional 800 shares during the period. Swedbank AB increased its holdings in shares of Becton, Dickinson and Company by 9.2% in the second quarter. Swedbank AB now owns 168,395 shares of the medical instruments supplier's stock valued at $29,006,000 after purchasing an additional 14,205 shares during the period. Baader Bank Aktiengesellschaft increased its holdings in shares of Becton, Dickinson and Company by 105.3% in the second quarter. Baader Bank Aktiengesellschaft now owns 1,977 shares of the medical instruments supplier's stock valued at $339,000 after purchasing an additional 1,014 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Becton, Dickinson and Company by 1.4% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 38,111 shares of the medical instruments supplier's stock valued at $6,565,000 after purchasing an additional 537 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $0.30 during trading on Monday, reaching $186.74. The stock had a trading volume of 1,227,724 shares, compared to its average volume of 1,592,393. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The business has a fifty day moving average price of $187.65 and a 200-day moving average price of $189.91. The stock has a market cap of $53.53 billion, a PE ratio of 33.59, a PEG ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the company posted $3.50 earnings per share. The business's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Analysts Set New Price Targets

BDX has been the subject of several recent research reports. Argus lifted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Piper Sandler reissued a "neutral" rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.